Vedavaag Systems (533056)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• P/E of 8.59 and P/B of 1.00 show a modest initial valuation, with price close to book value of ₹54.22.
• Dividend yield of 2.49% provides a small cash return to shareholders.
• Latest quarter is still profitable, with net profit of ₹2 Cr on sales of ₹26 Cr.
• Book value per share of ₹54.22 offers a rough floor near the current market price.

Concerns

• Sales growth is negative at -10.41%, and profit growth has dropped sharply by -48.57%.
• ROE of 3.81% and ROCE of 8.69% are weak, indicating poor capital efficiency.
• Piotroski F-Score of 3/9 suggests deteriorating fundamentals and financial stress.
• The stock has already moved from ₹15.10 to ₹54.00, so much of the recovery may be priced in without proven operating improvement.

AI Analysis

At ₹54, Vedavaag Systems has a market cap of ₹124 Cr, so it is a small-cap IT-enabled services company. A Graham-Buffett lens starts with numbers, not stories. The stock trades at 8.59 times earnings and almost exactly at book value of ₹54.22. That looks cheap at first glance. But cheapness must be validated by earning power. ROE is just 3.81%, and ROCE is 8.69% — far below what I would demand from a business trying to compound shareholder capital. Sales declined 10.41%, and profits collapsed 48.57%. The latest quarter shows ₹26 Cr of sales and only ₹2 Cr of net profit. The Piotroski F-Score of 3/9 adds to my caution, signalling weak financial health and operational deterioration. In Buffett's words, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Here, the price is not especially wonderful either: book value support is nice, but the business is not generating a satisfactory return on that book value. The 2.49% dividend yield offers some compensation, but a shrinking top line and falling profits are not signs of a resilient franchise. The 52-week range of ₹15.10 to ₹54.00 shows the market has already re-rated this stock dramatically; buying at the top of that range demands more operational proof. I cannot call Vedavaag a compounder. It could become a turnaround if management stabilises revenue and lifts ROE meaningfully, but today's evidence does not justify that conclusion. I would need several quarters of consistent improvement before paying even 8.59 times earnings. For now, this is a low-return, no-moat business trading at fair book value. I will keep it on the watchlist, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer